Voice-related Outcomes after Long-Term Androgen Treatment in Trans Males
Öz
Objective: The aim of this study was to evaluate voice-related outcomes of long-term androgen treatment in trans male individuals.
Methods: Trans male individuals who were under hormone treatment for at least one year were evaluated. Self-Perception of Voice Masculinity (SPVM) scale, adapted Transsexual Voice Questionnaire for trans males (a-TVQFtM), Voice-related Quality of Life (V-RQOL), and the mean fundamental frequency (f0) were used to assess voice outcomes.
Results: Of the thirteen trans male individuals in this study, the mean age was 26.15 years. The median SPVM was 4, which equated to “somewhat male”. The median f0 was 119 Hz and did not differ from Turkish cisgender male normative data. The median a-TVQFtM scores showed a decreasing trend and the median V-RQOL scale scores showed an increasing trend in accordance with the decrease of median f0 scores. Two individuals were within a gender ambiguous f0 range and a failure rate of 15.4% was observed. Of these two individuals who were still within a gender ambiguous f0 range, one perceived his voice as gender neutral, while the other one perceived his voice as very male.
Conclusion: Cross-sex hormone treatment was largely effective in voice masculinization for trans male individuals seeking treatment. Its pitch lowering effect is associated with a significant improvement in the voice-related quality of life of trans individuals, especially in vocal identity. In some cases, a cisgender male frequency may not be achieved. This situation should be evaluated with caution when discussing treatment outcomes and the necessity of additional interventions.
Anahtar Kelimeler
Kaynakça
- Bouman WP, Schwend AS, Motmans J, et al. Language and trans health. Int J Transgend. 2017;18(1):1-6.
- Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, Version 7. Int J Transgend. 2012;13(4):165-232.
- Hardy TL, Boliek CA, Wells K, Dearden C, Zalmanowitz C, Rieger JM. Pretreatment acoustic predictors of gender, femininity, and naturalness ratings in individuals with male-to-female gender identity. Am J Speech Lang Pathol. 2016;25(2):125-37.
- Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5(4):301-311.
- Gelfer MP, Mordaunt M. Pitch and intonation. In Adler RK, Hirsch S, Mordaunt M, editors. Voice and Communication Therapy for The Transgender/Transsexual Client: A Comprehensive Clinical Guide. San Diego, CA: Plural Publishing; 2012:187-224.
- Azul D, Nygren U, Södersten M, Neuschaefer-Rube C. Transmasculine people's voice function: A review of the currently available evidence. J Voice. 2017;31(2):261.e9-261.e23.
- Dacakis G, Davies S, Oates JM, Douglas JM, Johnston JR. Development and preliminary evaluation of the transsexual voice questionnaire for male-to-female transsexuals. J Voice. 2013;27(3):312-320.
- Dekker MJ, Wierckx K, Van Caenegem E, et al. A European Network for the Investigation of Gender Incongruence: Endocrine Part. J Sex Med. 2016;13(6):994-9.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Kulak Burun Boğaz
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
12 Ocak 2020
Gönderilme Tarihi
22 Kasım 2019
Kabul Tarihi
22 Aralık 2019
Yayımlandığı Sayı
Yıl 2020 Cilt: 6 Sayı: 1